229 related articles for article (PubMed ID: 29537306)
1. Deciphering metabonomics biomarkers-targets interactions for psoriasis vulgaris by network pharmacology.
Gu J; Li L; Wang D; Zhu W; Han L; Zhao R; Xu X; Lu C
Ann Med; 2018 Jun; 50(4):323-332. PubMed ID: 29537306
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target?
Huang T; Lin X; Meng X; Lin M
Acta Derm Venereol; 2014 Jul; 94(4):371-9. PubMed ID: 24217655
[TBL] [Abstract][Full Text] [Related]
3. Integrated serum metabolomics and network pharmacology approach to reveal the potential mechanisms of withanolides from the leaves of Datura metel L. on psoriasis.
Cheng Y; Liu Y; Tan J; Sun Y; Guan W; Jiang P; Yang B; Kuang H
J Pharm Biomed Anal; 2020 Jul; 186():113277. PubMed ID: 32302925
[TBL] [Abstract][Full Text] [Related]
4. Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry.
Li L; Chuan-Jian L; Ling H; Jing-Wen D; Ze-Hui H; Yu-Hong Y; Zhong-Zhao Z
Oncotarget; 2017 Nov; 8(56):95931-95944. PubMed ID: 29221177
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells: The driver of psoriasis.
Wang A; Bai Y
J Dermatol; 2020 Feb; 47(2):104-113. PubMed ID: 31833093
[TBL] [Abstract][Full Text] [Related]
6. A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression.
Gao Y; Xu T; Zhao YX; Ling-Hu T; Liu SB; Tian JS; Qin XM
Front Psychiatry; 2020; 11():667. PubMed ID: 32760300
[TBL] [Abstract][Full Text] [Related]
7. Mouse models of psoriasis and their relevance.
Nakajima K; Sano S
J Dermatol; 2018 Mar; 45(3):252-263. PubMed ID: 29226571
[TBL] [Abstract][Full Text] [Related]
8. Decryption of Active Constituents and Action Mechanism of the Traditional Uighur Prescription (BXXTR) Alleviating IMQ-Induced Psoriasis-Like Skin Inflammation in BALB/c Mice.
Pang X; Zhang K; Huang J; Wang H; Gao L; Wang T; Sun Y; Chen L; Wang J
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933541
[TBL] [Abstract][Full Text] [Related]
9. Anti-cytokine therapy in the treatment of psoriasis.
Kupetsky EA; Mathers AR; Ferris LK
Cytokine; 2013 Mar; 61(3):704-12. PubMed ID: 23410503
[TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.
Chamcheu JC; Adhami VM; Esnault S; Sechi M; Siddiqui IA; Satyshur KA; Syed DN; Dodwad SM; Chaves-Rodriquez MI; Longley BJ; Wood GS; Mukhtar H
Antioxid Redox Signal; 2017 Jan; 26(2):49-69. PubMed ID: 27393705
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-mass spectrometry method for discovering the metabolic markers to reveal the potential therapeutic effects of naringin on osteoporosis.
Li Y; Liu J; Zhou H; Liu J; Xue X; Wang L; Ren S
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Apr; 1194():123170. PubMed ID: 35228118
[TBL] [Abstract][Full Text] [Related]
12. LC-MS metabolomics reveal skin metabolic signature of psoriasis vulgaris.
Xiong Q; Zhong D; Li Q; Yu Y; Zhang S; Liang J; Zhang X
Exp Dermatol; 2023 Jun; 32(6):889-899. PubMed ID: 36999576
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effect of β, β-dimethylacryloyl alkannin on activated dendritic cells in an imiquimod-induced psoriasis mouse model.
Wang Y; Zhao J; Zhang L; Di T; Liu X; Lin Y; Zeng Z; Li P
Int J Clin Exp Pathol; 2015; 8(6):6665-73. PubMed ID: 26261548
[TBL] [Abstract][Full Text] [Related]
15. Emerging landscape in psoriasis management: From topical application to targeting biomolecules.
Rapalli VK; Singhvi G; Dubey SK; Gupta G; Chellappan DK; Dua K
Biomed Pharmacother; 2018 Oct; 106():707-713. PubMed ID: 29990862
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich α-2 glycoprotein is an innovative biomarker for psoriasis.
Nakajima H; Serada S; Fujimoto M; Naka T; Sano S
J Dermatol Sci; 2017 May; 86(2):170-174. PubMed ID: 28179066
[No Abstract] [Full Text] [Related]
17. Metabonomics Study on Serum Characteristic Metabolites of Psoriasis Vulgaris Patients With Blood-Stasis Syndrome.
Li L; Yao DN; Lu Y; Deng JW; Wei JA; Yan YH; Deng H; Han L; Lu CJ
Front Pharmacol; 2020; 11():558731. PubMed ID: 33312124
[TBL] [Abstract][Full Text] [Related]
18. Urinary metabonomics elucidate the therapeutic mechanism of Orthosiphon stamineus in mouse crystal-induced kidney injury.
Gao S; Chen W; Peng Z; Li N; Su L; Lv D; Li L; Lin Q; Dong X; Guo Z; Lou Z
J Ethnopharmacol; 2015 May; 166():323-32. PubMed ID: 25794803
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for psoriasis.
Gottlieb AB
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
[TBL] [Abstract][Full Text] [Related]
20. NMR-based metabonomics and correlation analysis reveal potential biomarkers associated with chronic atrophic gastritis.
Cui J; Liu Y; Hu Y; Tong J; Li A; Qu T; Qin X; Du G
J Pharm Biomed Anal; 2017 Jan; 132():77-86. PubMed ID: 27697573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
